Citations (80)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (17)
Lisa Rosenblatt, Michael S. Broder, Tanya G. K. Bentley, Eunice Chang, Sheila R. Reddy, Elya Papoyan & Joel Myers. (2017) Tolerability of central nervous system symptoms among HIV-1 infected efavirenz users: analysis of patient electronic medical record data. AIDS Care 29:8, pages 1067-1073.
Read now
Read now
Pornpimol Thamrongwonglert, Ploenchan Chetchotisakd, Siriluck Anunnatsiri & Piroon Mootsikapun. (2016) Improvement of lipid profiles when switching from efavirenz to rilpivirine in HIV-infected patients with dyslipidemia. HIV Clinical Trials 17:1, pages 12-16.
Read now
Read now
Sheng-Li Li, Peng Xu, Lei Zhang, Gui-Xiang Sun & Zhao-Jun Lu. (2015) Effectiveness and safety of rilpivirine, a non-nucleoside reverse transcriptase inhibitor, in treatment-naive adults infected with HIV-1: a meta-analysis. HIV Clinical Trials 16:1, pages 22-29.
Read now
Read now
Beatriz Larru, Jessica Eby & Elizabeth D Lowenthal. (2014) Antiretroviral treatment in HIV-1 infected pediatric patients: focus on efavirenz. Pediatric Health, Medicine and Therapeutics 5, pages 29-42.
Read now
Read now
Sheng-li Li, Peng Xu, Lei Zhang, Gui-xiang Sun & Zhao-jun Lu. (2014) Effectiveness and Safety of Rilpivirine, a Non-Nucleoside Reverse Transcriptase Inhibitor, in Treatment-Naive Adults Infected with HIV-1: A Meta-analysis. HIV Clinical Trials 15:6, pages 261-268.
Read now
Read now
Edwin DeJesus, Gerd Fätkenheuer, Catherine Orrell, Cunshan Wang, James Jones, Charles Craig, Margaret Tawadrous & Jayvant Heera. (2014) Efficacy and Safety of Lersivirine Versus Etravirine for the Treatment of HIV-1 Infection in Patients with Prior Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Use and Evidence of NNRTI Resistance: A Randomized Phase 2B Trial. HIV Clinical Trials 15:5, pages 209-217.
Read now
Read now
Peter Derek Christian Leutscher, Chalotte Stecher, Merete Storgaard & Carsten Schade Larsen. (2013) Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects. Scandinavian Journal of Infectious Diseases 45:8, pages 645-651.
Read now
Read now
Michael A Horberg & Daniel B Klein. (2010) An update on the use of Atripla® in the treatment of HIV in the United States. HIV/AIDS - Research and Palliative Care 2, pages 135-140.
Read now
Read now
G. I. T. Cavalcante, V. L. M. Capistrano$suffix/text()$suffix/text(), F. S. D. Cavalcante, S. M. M. Vasconcelos, D. S. Macêdo, F. C. F. Sousa, D. J. Woods & M. M. F. Fonteles. (2010) Implications of Efavirenz for Neuropsychiatry: A Review. International Journal of Neuroscience 120:12, pages 739-745.
Read now
Read now
Mark de Serres, Lee Moss, James Sigafoos, Andrea Sefler, Stephen Castellino, Gary Bowers & Cosette Serabjit-Singh. (2010) The disposition and metabolism of GW695634: A non-nucleoside reverse transcriptase inhibitor (NNRTi) for treatment of HIV/AIDS. Xenobiotica 40:6, pages 437-445.
Read now
Read now
Gabriele Arendt, Dominique de Nocker, Hans-Juergen von Giesen & Thorsten Nolting. (2007) Neuropsychiatric side effects of efavirenz therapy. Expert Opinion on Drug Safety 6:2, pages 147-154.
Read now
Read now
Roberto Manfredi, Leonardo Calza & Francesco Chiodo. (2005) Prospective, Open-Label Comparative Study of Liver Toxicity in an Unselected Population of HIV-Infected Patients Treated for the First Time with Efavirenz or Nevirapine. HIV Clinical Trials 6:6, pages 302-311.
Read now
Read now
J. Santos, R. Palacios, M. López, M.C. Gálvez, F. Lozano, J. de la Torre, M.J. Ríos, L.F. López-Cortés, A. Rivero & M. Torres-Tortosa. (2005) Simplicity and Efficacy of a Once-Daily Antiretroviral Regimen with Didanosine, Lamivudine, and Efavirenz in Naïve Patients: The VESD Study. HIV Clinical Trials 6:6, pages 320-328.
Read now
Read now
F. Faggian, E. Lattuada, M. Lanzafame, D. Antolini, E. Concia & S. Vento. (2005) Recreational substance use and tolerance of efavirenz in HIV-1 infected patients. AIDS Care 17:7, pages 908-910.
Read now
Read now
Trevor Hawkins, Cindy Geist, Ben Young, A. Giblin, Renee C. Mercier, Karla Thornton & Richard Haubrich. (2005) Comparison of Neuropsychiatric Side Effects in an Observational Cohort of Efavirenz- and Protease Inhibitor-Treated Patients. HIV Clinical Trials 6:4, pages 187-196.
Read now
Read now
Trevor Hawkins, Cindy Geist, Ben Young, A. Giblin, Renee C. Mercier, Karla Thornton & Richard Haubrich. (2005) Comparison of Neuropsychiatric Side Effects in an Observational Cohort of Efavirenz- and Protease Inhibitor-Treated Patients. HIV Clinical Trials 6:4, pages 187-196.
Read now
Read now
Hans Jürgen von Giesen, Hubertus Köller, Dominique de Nocker, Bernhard A. Haslinger & Gabriele Arendt. (2003) Long-Term Safety and Efficacy of NNRTI Within the Central Nervous System. HIV Clinical Trials 4:6, pages 382-390.
Read now
Read now
Articles from other publishers (63)
Ameet N. Dravid, Anant S. Pilawan, S. Anuradha, Dnyanesh N. Morkar, John T. Ramapuram, Kulkarni Milind Madhukarrao, K. Sunil Naik, Milind Bhrusundi, K.R. Raveendra, Siddabathuni Nageswaramma & Vinay Kulkarni. (2023) Safety of low dose efavirenz regimen in Indian adults with HIV-1 infection: Insights from a phase 4 interventional randomised trial. Medicine 102:44, pages e35643.
Crossref
Crossref
Noelia Fernández-Bargiela, Sandra Rotea-Salvo, Luis Margusino-Framiñán, Vanesa Balboa-Barreiro, Isabel Martín-Herranz, Ángeles Castro-Iglesias, Álvaro Mena-De-Cea, Soledad López-Calvo, Pilar Vázquez-Rodríguez, Enrique Míguez-Rey & Purificación Cid-Silva. (2022) Discontinuation due to neuropsychiatric adverse events with efavirenz- and dolutegravir-based antiretroviral therapy: a comparative real-life study. European Journal of Hospital Pharmacy 29:4, pages 207-211.
Crossref
Crossref
Zaikuan J. YuEric P. MosherNamandjé N. Bumpus. (2021) Pharmacogenomics of Antiretroviral Drug Metabolism and Transport. Annual Review of Pharmacology and Toxicology 61:1, pages 565-585.
Crossref
Crossref
Nathana Ciniglia, Rossano Kepler Alvim Fiorelli & Lucia Marques Vianna. (2020) Valeriana Officinalis no Controle da Ansiedade em Pessoas Vivendo com HIV/aids – há uma possibilidade?. Revista Neurociências 28, pages 1-17.
Crossref
Crossref
Sirichai Wiriyatanakorn & Somnuek Sungkanuparph. (2019) Switching Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) to TDF/FTC/Rilpivirine (RPV) vs Continuing TDF/FTC/EFV in HIV-infected Patients with Virological Suppression: A Randomized Controlled Trial. Open Forum Infectious Diseases.
Crossref
Crossref
Sabina Mugusi, Eliford Ngaimisi, Mohammed Janabi, Ferdinand Mugusi, Omary Minzi, Eric Aris, Muhammad Bakari, Leif Bertilsson, Juergen Burhenne, Eric Sandstrom & Eleni Aklillu. (2018) Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin. European Journal of Clinical Pharmacology 74:11, pages 1405-1415.
Crossref
Crossref
Manoranjenni Chetty, Theresa Cain, Janak Wedagedera, Amin Rostami-Hodjegan & Masoud Jamei. (2018) Application of Physiologically Based Pharmacokinetic (PBPK) Modeling Within a Bayesian Framework to Identify Poor Metabolizers of Efavirenz (PM), Using a Test Dose of Efavirenz. Frontiers in Pharmacology 9.
Crossref
Crossref
Nadezda Apostolova, Ana Blas-Garcia, Maria J. Galindo & Juan V. Esplugues. (2017) Efavirenz: What is known about the cellular mechanisms responsible for its adverse effects. European Journal of Pharmacology 812, pages 163-173.
Crossref
Crossref
Birgit Viira, Alfonso T. García-Sosa & Uko Maran. (2017) Chemical structure and correlation analysis of HIV-1 NNRT and NRT inhibitors and database-curated, published inhibition constants with chemical structure in diverse datasets. Journal of Molecular Graphics and Modelling 76, pages 205-223.
Crossref
Crossref
Amanda Häggblom, Stefan Lindbäck, Magnus Gisslén, Leo Flamholc, Bo Hejdeman, Andreas Palmborg, Amy Leval, Eva Herweijer, Sverrir Valgardsson & Veronica Svedhem. (2017) HIV drug therapy duration; a Swedish real world nationwide cohort study on InfCareHIV 2009-2014. PLOS ONE 12:2, pages e0171227.
Crossref
Crossref
Paul Curley, Rajith K. R. Rajoli, Darren M. Moss, Neill J. Liptrott, Scott Letendre, Andrew Owen & Marco Siccardi. (2017)
Efavirenz Is Predicted To Accumulate in Brain Tissue: an
In Silico
,
In Vitro
, and
In Vivo
Investigation
. Antimicrobial Agents and Chemotherapy 61:1.
Crossref
Crossref
Collen MasimirembwaCollet DandaraPeter Derek Christian Leutscher. (2016) Rolling out Efavirenz for HIV Precision Medicine in Africa: Are We Ready for Pharmacovigilance and Tackling Neuropsychiatric Adverse Effects?. OMICS: A Journal of Integrative Biology 20:10, pages 575-580.
Crossref
Crossref
Glenn J. Treisman & Olivia Soudry. (2016) Neuropsychiatric Effects of HIV Antiviral Medications. Drug Safety 39:10, pages 945-957.
Crossref
Crossref
Fred S. Sarfo, Maame A. Sarfo & David Chadwick. (2016) Incidence and risk factors for neuropsychiatric events among Ghanaian HIV patients on long-term non-nucleoside reverse transcriptase inhibitor-based therapy. eNeurologicalSci 3, pages 21-25.
Crossref
Crossref
Nadezda Apostolova, Haryes A. Funes, Ana Blas-Garcia, Maria J. Galindo, Angeles Alvarez & Juan V. Esplugues. (2015) Efavirenz and the CNS: what we already know and questions that need to be answered. Journal of Antimicrobial Chemotherapy 70:10, pages 2693-2708.
Crossref
Crossref
Wissam K. Kabbara & Wijdan H. Ramadan. (2015) Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults. Journal of Infection and Public Health 8:5, pages 409-417.
Crossref
Crossref
H. Jeulin, M. Foissac, L. Boyer, N. Agrinier, P. Perrier, A. Kennel, A. Velay, F. Goehringer, S. Henard, C. Rabaud, T. May & E. Schvoerer. (2014) Real-life rilpivirine resistance and potential emergence of an E138A-positive HIV strain in north-eastern France. Journal of Antimicrobial Chemotherapy 69:11, pages 3095-3102.
Crossref
Crossref
Shui Shan Lee, Kin Wang To, Man Po Lee, Ngai Sze Wong, Denise PC Chan, Patrick CK Li, Siu Wai Cheung & Raphael CY Chan. (2013) Sleep quality in efavirenz-treated Chinese HIV patients – comparing between GT and GG genotype of CYP2B6-516 G/T polymorphisms. International Journal of STD & AIDS 25:3, pages 193-200.
Crossref
Crossref
Michael S. Abers, Wayne X. Shandera & Joseph S. Kass. (2013) Neurological and Psychiatric Adverse Effects of Antiretroviral Drugs. CNS Drugs 28:2, pages 131-145.
Crossref
Crossref
Jackson K Mukonzo, Alphonse Okwera, Neoline Nakasujja, Henry Luzze, Deogratious Sebuwufu, Jasper Ogwal-Okeng, Paul Waako, Lars L Gustafsson & Eleni Aklillu. (2013) Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study. BMC Infectious Diseases 13:1.
Crossref
Crossref
T. Isaacs, M. R. Ngwanya, S. Dlamini & R. J. Lehloenya. (2013) Annular erythema and photosensitivity as manifestations of efavirenz-induced cutaneous reactions: a review of five consecutive cases. Journal of Antimicrobial Chemotherapy 68:12, pages 2871-2874.
Crossref
Crossref
Almudena Sánchez Martín, Salvador Cabrera Figueroa, Raquel Cruz Guerrero, Liliana Porras Hurtado, Alfonso Dominguez-Gil Hurlé & Ángel Carracedo Álvarez. (2013) Impact of pharmacogenetics on CNS side effects related to efavirenz. Pharmacogenomics 14:10, pages 1167-1178.
Crossref
Crossref
S. Lambert-Niclot, C. Charpentier, A. Storto, D. B. Fofana, C. Soulie, S. Fourati, B. Visseaux, M. Wirden, L. Morand-Joubert, B. Masquelier, P. Flandre, V. Calvez, D. Descamps & A.- G. Marcelin. (2013) Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses. Journal of Antimicrobial Chemotherapy 68:6, pages 1237-1242.
Crossref
Crossref
Calvin J. Cohen, Jean-Michel Molina, Isabel Cassetti, Ploenchan Chetchotisakd, Adriano Lazzarin, Chloe Orkin, Frank Rhame, Hans-Jürgen Stellbrink, Taisheng Li, Herta Crauwels, Laurence Rimsky, Simon Vanveggel, Peter Williams & Katia Boven. (2013) Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials. AIDS 27:6, pages 939-950.
Crossref
Crossref
Pietro Vernazza, Cunshan Wang, Anton Pozniak, Elizabeth Weil, Piotr Pulik, David. A. Cooper, Richard Kaplan, Adriano Lazzarin, Hernan Valdez, James Goodrich, Julie Mori, Charles Craig & Margaret Tawadrous. (2013) Efficacy and Safety of Lersivirine (UK-453,061) Versus Efavirenz in Antiretroviral Treatment–Naive HIV-1–Infected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes 62:2, pages 171-179.
Crossref
Crossref
Luis B. Tovar-y-Romo, Namandjé N. Bumpus, Daniel Pomerantz, Lindsay B. Avery, Ned Sacktor, Justin C. McArthur & Norman J. Haughey. (2012) Dendritic Spine Injury Induced by the 8-Hydroxy Metabolite of Efavirenz. Journal of Pharmacology and Experimental Therapeutics 343:3, pages 696-703.
Crossref
Crossref
Pedro Cahn. (2012) Rilpivirine in the treatment of HIV infection: evidence from the ECHO and THRIVE studies. Clinical Investigation 2:11, pages 1133-1144.
Crossref
Crossref
M Siccardi, L Almond, A Schipani, C Csajka, C Marzolini, C Wyen, N H Brockmeyer, M Boffito, A Owen & D Back. (2012) Pharmacokinetic and Pharmacodynamic Analysis of Efavirenz Dose Reduction Using an In Vitro–In Vivo Extrapolation Model. Clinical Pharmacology & Therapeutics 92:4, pages 494-502.
Crossref
Crossref
A Winston, R Puls, SJ Kerr, C Duncombe, PCK Li, JM Gill, SD Taylor‐Robinson, S Emery & DA Cooper. (2011)
Dynamics of cognitive change in
HIV
‐infected individuals commencing three different initial antiretroviral regimens: a randomized, controlled study
. HIV Medicine 13:4, pages 245-251.
Crossref
Crossref
Sofia A. Pereira, Riccardo Wanke, M. Matilde Marques, Emília C. Monteiro & Alexandra M.M. Antunes. 2012. Advances in Molecular Toxicology Volume 6. Advances in Molecular Toxicology Volume 6
1
39
.
Martina Penazzato & Carlo Giaquinto. (2011) Role of Non-Nucleoside Reverse Transcriptase Inhibitors in Treating HIV-Infected Children. Drugs 71:16, pages 2131-2149.
Crossref
Crossref
Christopher A. Kenedi & Harold W. Goforth. (2011) A Systematic Review of the Psychiatric Side-Effects of Efavirenz. AIDS and Behavior 15:8, pages 1803-1818.
Crossref
Crossref
C. Wyen, H. Hendra, M. Siccardi, M. Platten, H. Jaeger, T. Harrer, S. Esser, J. R. Bogner, N. H. Brockmeyer, B. Bieniek, J. Rockstroh, C. Hoffmann, A. Stoehr, C. Michalik, V. Dlugay, A. Jetter, H. Knechten, H. Klinker, A. Skaletz-Rorowski, G. Fatkenheuer, D. Egan, D. J. Back, A. Owen, S. Dupke, A. Carganico, A. Baumgarten, S. Koeppe, P. Kreckel, E. Lauenroth-Mai, F. Schlote, C. Schuler, M. Freiwald, M. Rausch, J. Golz, A. Moll, M. Zeitz, N. Brockmeyer, M. Hower, S. Reuter, T. Harrer, S. Esser, S. Staszewski, A. Plettenberg, S. Fenske, T. Buhk, H.-J. Stellbrink, R. Schmidt, B. Kuhlmann, F. Mosthaf, A. Rieke, S. Scholten, H. Jaeger, E. Jaegel-Guedes, R. Volkert, W. Becker, H. Hartl, A. Mutz, A. Ulmer, B. Frietsch & M. Muller. (2011) Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. Journal of Antimicrobial Chemotherapy 66:9, pages 2092-2098.
Crossref
Crossref
Koen Andries, Ann Debunne, Thomas N. Kakuda, Michael Kukla, Ruud Leemans, Johan Vingerhoets, Brian Woodfall & Marie-Pierre de Béthune. 2011. Antiviral Drugs. Antiviral Drugs
71
84
.
Jérôme Guillemont, Katia Boven, Herta Crauwels & Marie-Pierre de Béthune. 2011. Antiviral Drugs. Antiviral Drugs
59
69
.
Calvin J Cohen, Jaime Andrade-Villanueva, Bonaventura Clotet, Jan Fourie, Margaret A Johnson, Kiat Ruxrungtham, Hao Wu, Carmen Zorrilla, Herta Crauwels, Laurence T Rimsky, Simon Vanveggel & Katia Boven. (2011) Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. The Lancet 378:9787, pages 229-237.
Crossref
Crossref
Jean-Michel Molina, Pedro Cahn, Beatriz Grinsztejn, Adriano Lazzarin, Anthony Mills, Michael Saag, Khuanchai Supparatpinyo, Sharon Walmsley, Herta Crauwels, Laurence T Rimsky, Simon Vanveggel & Katia Boven. (2011) Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. The Lancet 378:9787, pages 238-246.
Crossref
Crossref
María Velasco, Juan Antonio Pareja, Juan Emilio Losa, José Francisco Valverde, Alfredo Espinosa & Carlos Gujarro. (2011) Dream changes following initiation of efavirenz treatment. Medicina Clínica 136:3, pages 103-105.
Crossref
Crossref
Camille E. Introcaso, Janet M. Hines & Carrie L. Kovarik. (2010) Cutaneous toxicities of antiretroviral therapy for HIV. Journal of the American Academy of Dermatology 63:4, pages 563-569.
Crossref
Crossref
Anton L Pozniak, Javier Morales-Ramirez, Elly Katabira, Dewald Steyn, Sergio H Lupo, Mario Santoscoy, Beatriz Grinsztejn, Kiat Ruxrungtham, Laurence T Rimsky, Simon Vanveggel & Katia Boven. (2010) Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial. AIDS 24:1, pages 55-65.
Crossref
Crossref
Christine Katlama, Richard Haubrich, Jacob Lalezari, Adriano Lazzarin, José V Madruga, Jean-Michel Molina, Mauro Schechter, Monika Peeters, Gaston Picchio, Johan Vingerhoets, Brian Woodfall & Goedele De Smedt. (2009) Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS 23:17, pages 2289-2300.
Crossref
Crossref
F. Maggiolo. (2009) Efavirenz: a decade of clinical experience in the treatment of HIV. Journal of Antimicrobial Chemotherapy 64:5, pages 910-928.
Crossref
Crossref
S Kiertiburanakul, K Malathum, S Watcharananan, B Sathapatayavongs & S Sungkanuparph. (2009) Predicting factors for unsuccessful switching from nevirapine to efavirenz in HIV-infected patients who developed nevirapine-associated skin rash. International Journal of STD & AIDS 20:3, pages 176-179.
Crossref
Crossref
Calvin J Cohen, Daniel S Berger, Gary Blick, Howard A Grossman, Dushyantha T Jayaweera, Peter Shalit, Melanie Thompson, Monika Peeters, Marie-Pierre de Béthune, Ellen Voorspoels, Rebecca Mack & Brian Woodfall. (2009) Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trial. AIDS 23:3, pages 423-426.
Crossref
Crossref
Julio Montaner, Patrick Yeni, Nathan N. Clumeck, Gerd Fätkenheuer, Jose Gatell, Phillip Hay, Elena Seminari, Monika P. Peeters, Monika Schöller‐Gyüre, Myriam Simonts & Brian Woodfall. (2008) Safety, Tolerability, and Preliminary Efficacy of 48 Weeks of Etravirine Therapy in a Phase IIb Dose‐Ranging Study Involving Treatment‐Experienced Patients with HIV‐1 Infection. Clinical Infectious Diseases 47:7, pages 969-978.
Crossref
Crossref
Jennifer King & Judith A Aberg. (2008) Clinical impact of patient population differences and genomic variation in efavirenz therapy. AIDS 22:14, pages 1709-1717.
Crossref
Crossref
Ushma Mehta & Gary Maartens. (2007) Is it safe to switch between efavirenz and nevirapine in the event of toxicity?. The Lancet Infectious Diseases 7:11, pages 733-738.
Crossref
Crossref
Matilde Sánchez-CondeRosario PalaciosJosé SanzSonia Rodríguez-NovoaPablo RivasJesús SantosJulio SolaVictor AsensiCarmen de MendozaVicente EstradaPablo BarreiroJuan González-LahozInmaculada Jiménez-NacherVincent Soriano. (2007) Efficacy and Safety of a Once Daily Regimen with Efavirenz, Lamivudine, and Didanosine, with and without Food, as Initial Therapy for HIV Infection: The ELADI Study. AIDS Research and Human Retroviruses 23:10, pages 1237-1241.
Crossref
Crossref
TA Rihs, K Begley, DE Smith, J Sarangapany, A Callaghan, M Kelly, JJ Post & J Gold. (2006) Efavirenz and chronic neuropsychiatric symptoms: a cross-sectional case control study. HIV Medicine 7:8, pages 544-548.
Crossref
Crossref
W Manosuthi, S Thongyen, N Chumpathat, K Muangchana & S Sungkanuparph. (2006) Incidence and risk factors of rash associated with efavirenz in HIV-infected patients with preceding nevirapine-associated rash. HIV Medicine 7:6, pages 378-382.
Crossref
Crossref
Víctor Julián Moreno-Cuerda, Montserrat Morales-Conejo & Rafael Rubio. (2006) Efectos secundarios potencialmente graves del tratamiento antirretroviral. Medicina Clínica 126:19, pages 744-749.
Crossref
Crossref
Christine Danel, Raoul Moh, Amani Anzian, Yao Abo, Henri Chenal, Calixte Guehi, Delphine Gabillard, Souleymane Sorho, François Rouet, Serge Eholié & Xavier Anglaret. (2006) Tolerance and Acceptability of an Efavirenz-Based Regimen in 740 Adults (Predominantly Women) in West Africa. JAIDS Journal of Acquired Immune Deficiency Syndromes 42:1, pages 29-35.
Crossref
Crossref
Lois S. Lee & Lingtak‐Neander Chan. (2012) Evaluation of a Sex‐Based Difference in the Pharmacokinetics of Digoxin. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 26:1, pages 44-50.
Crossref
Crossref
F. Gutierrez, A. Navarro, S. Padilla, R. Anton, M. Masia, J. Borras & A. Martin-Hidalgo. (2005) Prediction of Neuropsychiatric Adverse Events Associated with Long-Term Efavirenz Therapy, Using Plasma Drug Level Monitoring. Clinical Infectious Diseases 41:11, pages 1648-1653.
Crossref
Crossref
Charles Raines, Olivia Radcliffe & Glenn J. Treisman. (2005) Neurologic and Psychiatric Complications of Antiretroviral Agents. Journal of the Association of Nurses in AIDS Care 16:5, pages 35-48.
Crossref
Crossref
M. Hartmann, J. Brust, D. Schuster, F. Mosthaf, M. Procaccianti, J. A. Rump, H. Klinker & D. Petzoldt. (2005) Arzneimittelexantheme bei Therapie der HIV-Infektion mit Efavirenz und NevirapinRashes in HIV-infected patients undergoing therapy with nevirapine or efavirenz. Der Hautarzt 56:9, pages 847-853.
Crossref
Crossref
Carmina R Fumaz, Jose A Munoz-Moreno, José Moltó, Eugènia Negredo, Maria José Ferrer, Guillem Sirera, Núria Pérez-Alvarez, Guadalupe Gómez, David Burger & Bonaventura Clotet. (2005) Long-Term Neuropsychiatric Disorders on Efavirenz-Based Approaches. JAIDS Journal of Acquired Immune Deficiency Syndromes 38:5, pages 560-565.
Crossref
Crossref
Zhijun Zhang, Robert Hamatake & Zhi Hong. (2016) Clinical Utility of Current NNRTIs and Perspectives of New Agents in This Class under Development. Antiviral Chemistry and Chemotherapy 15:3, pages 121-134.
Crossref
Crossref
Roberto Manfredi, Leonardo Calza & Francesco Chiodo. (2004) Efavirenz Versus Nevirapine in Current Clinical Practice: A Prospective, Open-Label Observational Study. JAIDS Journal of Acquired Immune Deficiency Syndromes 35:5, pages 492-502.
Crossref
Crossref
W Manosuthi, S Sungkanuparph, A Vibhagool, S Rattanasiri & A Thakkinstian. (2004) Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naive patients with advanced HIV infection. HIV Medicine 5:2, pages 105-109.
Crossref
Crossref
Roberto Manfredi, Leonardo Calza & Francesco Chiodo. (2004) Gynecomastia, Lipodystrophy Syndrome, and Dyslipidemia Occurring or Worsening During Antiretroviral Regimens Other Than Protease Inhibitor-Based Ones. JAIDS Journal of Acquired Immune Deficiency Syndromes 35:1, pages 99-102.
Crossref
Crossref
Roberto Manfredi. (2003) HIV infection, antiretroviral therapy, and hepatic function. Emerging epidemiological, pathogenetic, and clinical issues, and their consequences on disease management. AIDS 17:15, pages 2253-2256.
Crossref
Crossref
David Goldenberg & Ewald Horwath. (2016) Letters to the Editor. Journal of the International Association of Physicians in AIDS Care 2:2, pages 88-90.
Crossref
Crossref